Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Although effects of low concentrations of agonist were not a
2024-10-08

Although effects of low concentrations of agonist were not as thoroughly documented for heteromeric receptors such as the major ZM 447439 australia α4β2 nAChR, a similar mechanism of action was described to explain the potentiation of these receptors with low concentrations of acetylcholine-esteras
-
Phospholipases cleave membrane phospholipids from inflammato
2024-10-08

Phospholipases cleave membrane phospholipids from inflammatory cells, activated platelets, erythrocytes, adipocytes and cancer GX15-070 (Aoki et al., 2008, Neidlinger et al., 2006). Several reports have analysed the role of LPA and its receptors in the pathogenesis of RA. Zhao et al. reported that
-
However there are studies revealing
2024-10-08

However, there are studies revealing the “dark side” of autophagy at later stages in cancers, when oncogenes (mainly K-ras and B-raf) are activated and/or tumour suppressors such as PTEN and p53 are inactivated. These studies are based on the use of GEMM and deletions of essential autophagy genes (A
-
A unique finding in this study is that LO influences
2024-10-08

A unique finding in this study is that 12/15-LO influences CREB phosphorylation in the murine brain. While previous reports have found that knockout of 5-lipoxygenase, a related enzyme that also uses arachidonic PD 0332991 for substrate, can regulate CREB phosphoryation in the context of Alzheimer'
-
The relationship between the apelinergic and opioid systems
2024-10-08

The relationship between the apelinergic and opioid systems has been previously reported (Lv et al., 2011, Yang et al., 2010). Lv and colleagues showed that naloxone has a suppressive effect on apelin-induced depression-like behavior in mice (Lv et al., 2012a). Furthermore, heterodimerization of GPC
-
Apelin APJ triggers a variety of cellular signaling pathways
2024-10-08

Apelin/APJ triggers a variety of cellular signaling pathways (Fig. 1). Recent studies from our laboratory showed that apelin-13 induces vascular smooth muscle cell (VSMC) proliferation by the upregulation of Cyclin D1 expression, which is involved in an ERK-dependent activation of Jagged-1/Notch3 si
-
In the early s in
2024-10-08

In the early 2000s, in addition to above-mentioned plant derived compounds, several peptide fragments from protein sources (e.g. gelatin, egg yolk, meat, fish, chicken, legumes) have been also confirmed as potential natural antioxidants and extensive studies about bioactive peptides have been conduc
-
The AHR potentially enhances IDO expression possibly via cro
2024-10-03

The AHR potentially enhances IDO-expression, possibly via crosstalk with several inflammatory signaling pathways (shown by now for IL6 and ‘signal transducer and activator of transcription’ (STAT) 3, and for NFκB, toll like receptor-pathways) [56,59,60]. IDO metabolizes Trp to kynurenines, which are
-
br Conflict of interest br
2024-10-03

Conflict of interest Financial support Acknowledgments This work was supported by the Japanese Millennium project. We thank all members of the Center for Genomic Medicine of RIKEN and Dainippon-Sumitomo Pharma Co., Ltd. for supporting this study. We are also grateful to members of the Hiros
-
br Introduction Myasthenia gravis MG is an autoimmune
2024-10-03

Introduction Myasthenia gravis (MG) is an autoimmune disease characterised by failure of transmission at the neuromuscular junction (NMJ). In 80–85% of myasthenia gravis patients, the disease is mediated by antibodies to the nicotinic Oleandrin receptor (AChR; (Lindstrom et al., 1976). Many inves
-
This raises an important question May the lack of
2024-10-03

This raises an important question: May the lack of ethnolinguistic theories and of explicit references to language be related to the lack of contact with other groups and their languages? For the past few centuries at least, the Aché seem to have been culturally and linguistically isolated (Hill and
-
The earliest appearance of tumors occurred at
2024-10-01

The earliest appearance of tumors occurred at 12 months and the latest at 24 months, with an average onset at 18 months (Fig. 1B). This would be roughly equivalent to cancer presenting in a patient between 60 and 70 years of age. In transgenic animals, autotaxin vegf inhibitor was relatively increa
-
Introduction Lysophosphatidic acid LPA is a key serum
2024-10-01

Introduction Lysophosphatidic urotensin ii (LPA) is a key, serum-borne phospholipid, regulating a number of cellular processes such as proliferation, migration and differentiation through its interaction with G-protein coupled receptors. LPA receptor signaling has been implicated in several diseas
-
Idarubicin HCl sale If the lack of specificity and the high
2024-10-01

If the lack of specificity and the high pleiotropy may represent a problem in view of the potential chemotherapeutic features of autophagy-inducing agents, it Idarubicin HCl sale may switch into an advantage in the case of chemopreventive strategies. In fact, as non-pharmacologic interventions such
-
Nowadays more than kinases have been identified of human gen
2024-10-01

Nowadays, more than 500 kinases have been identified of human genome [2]. Imatinib (Gleevec) was the first tyrosine kinase inhibitor approved by the US Food and Drug Administration (FDA) for the treatment of chronic myeloid leukemia [3], and kinases have become an attractive target for the developme
16616 records 81/1108 page Previous Next First page 上5页 8182838485 下5页 Last page